University of California San Francisco
Give to UCSF<p>UCSF was recently recognized as a 2011 gold-level recipient of the American Heart Association’s Start! Fit-Friendly Companies Recognition program. </p>
A UCSF study holds clues to why an emerging clinical trials option for heart attack patients has not been as successful as anticipated. Treatment of human hearts with bone marrow cells has led to limited to no success in improving their heart function even though a similar method has been much more effective in rodents.
<p>High blood pressure affects 1 billion people worldwide. At least 30 percent of individual variation in blood pressure is due to genes. The largest-ever study to search for risk genes has just been published and homed in on 16 new genes. But most of the genetic contribution to blood pressure remains elusive. A new research approach may be needed.</p>
A new and simple risk score may aid physicians in gauging the likelihood that a common drug will cause a hemorrhagic stroke or other major bleeding in patients with atrial fibrillation, potentially allowing wider but safer use of the effective drug.
UCSF Medical Center has reduced hospital readmissions for older heart failure patients by nearly a third, thanks to a program designed to identify ways for hospitals to improve patients' transitions to their homes.
Outcomes of bypass surgery to repair blocked arteries in the legs tend to be better in the roughly one-in-five people who have inherited a specific genetic variation from both parents, according to a study presented at the late-breaking clinical trials session of the Vascular Annual Meeting in Chicago on June 18, 2011.